Denduluri Sahitya K, Scott Bryan, Lamplot Joseph D, Yin Liangjun, Yan Zhengjian, Wang Zhongliang, Ye Jixing, Wang Jing, Wei Qiang, Mohammed Maryam K, Haydon Rex C, Kang Richard W, He Tong-Chuan, Athiviraham Aravind, Ho Sherwin H, Shi Lewis L
1 Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Pritzker School of Medicine , Chicago, Illinois.
2 Ministry of Education Key Laboratory of Diagnostic Medicine, The Affiliated Hospitals of Chongqing Medical University , Chongqing, China .
Tissue Eng Part C Methods. 2016 Mar;22(3):280-9. doi: 10.1089/ten.tec.2015.0244.
Investigating the cellular processes underlying tendon healing can allow researchers to improve long-term outcomes after injury. However, conducting meaningful studies to uncover the injury healing mechanism at cellular and molecular levels remains challenging. This is due to the inherent difficulty in isolating, culturing, and expanding sufficient primary tenocytes, due to their limited proliferative capacity and short lifespan. In this study, we sought to establish a novel line of immortalized mouse Achilles tenocytes (iMATs) with primary tenocyte properties, but increased proliferative capacity suitable for extensive in vitro experimentation. We show that isolated primary mouse Achilles tenocytes (pMATs) can be effectively immortalized using a piggyBac transposon expressing SV40 large T antigen flanked by FLP recombination target site (FRT). The resulting iMATs exhibit markedly greater proliferation and survival, which can be reversed with FLP recombinase. Furthermore, iMATs express the same set of tendon-specific markers as that of primary cells, although in lower levels, and respond similarly to exogenous stimulation with bone morphogenetic protein 13 (BMP13) as has been previously reported with pMATs. Taken together, our results suggest that iMATs acquire long-term proliferative capacity while maintaining tenogenic properties. We believe that iMATs are a suitable model for studying not only the native cellular processes involved in injury and healing, but also potential therapeutic agents that may augment the stability of tendon repair.
研究肌腱愈合背后的细胞过程可以让研究人员改善损伤后的长期预后。然而,进行有意义的研究以揭示细胞和分子水平上的损伤愈合机制仍然具有挑战性。这是由于分离、培养和扩增足够数量的原代肌腱细胞存在固有困难,因为它们的增殖能力有限且寿命较短。在本研究中,我们试图建立一种具有原代肌腱细胞特性但增殖能力增强的新型永生化小鼠跟腱细胞系(iMATs),以适用于广泛的体外实验。我们表明,使用表达SV40大T抗原且两侧带有FLP重组靶位点(FRT)的piggyBac转座子,可以有效地使分离的原代小鼠跟腱细胞(pMATs)永生化。所得的iMATs表现出明显更强的增殖和存活能力,这可以通过FLP重组酶逆转。此外,iMATs表达与原代细胞相同的一组肌腱特异性标志物,尽管表达水平较低,并且对外源性骨形态发生蛋白13(BMP13)刺激的反应与先前报道的pMATs相似。综上所述,我们的结果表明iMATs在保持肌腱生成特性的同时获得了长期增殖能力。我们相信iMATs不仅是研究损伤和愈合中涉及的天然细胞过程的合适模型,也是研究可能增强肌腱修复稳定性的潜在治疗药物的合适模型。